Claims for Patent: 4,701,442

Summary for Patent: 4,701,442

Title:	Treatment of symptoms of neoplastic diseases with nucleoproteins
Abstract:	A process for preparing nucleoproteic material which comprises immersing organic material into a suitable solvent for a sufficient time to extract nucleoproteins from said material, adding a sufficient amount of an acid to form a precipitate of nucleoproteic material, and recovering said nucleoproteic material precipitate. A composition of nucleoproteic material produced according to this process. A method for alleviating symptoms of neoplastic diseases which comprises sterilizing the composition of nucleoproteic material, preparing a formulation comprising an effective amount of said sterilized composition, and administering said formulation to a patient having symptoms of a neoplastic disease.
Inventor(s):	Revici; Emanuel (New York, NY)
Assignee:	Avram; Elena (New York, NY)
Application Number:	06/744,341
Patent Claims:	1. A process for preparing pharmaceutical preparations of nucleoproteic material for administration to a subject for treatment of symptoms of neoplastic diseases which comprises: immersing a carp or pig organ into a solvent for a sufficient time to extract nucleoproteins from said organ; adding a sufficient amount of an acid to form a precipitate of nucleoproteic material; sterilizing said nucleoproteic precipitate; and preparing a formulation comprising a sterile water or saline suspension containing about 5 to 50% of said sterilized nucleoproteic precipitate. 2. The process of claim 1 wherein said solvent is water. 3. The process of claim 1 wherein said water is heated to boiling. 4. The process of claim 1 wherein said solvent further comprises an alkaline component. 5. The process of claim 1 wherein said solvent has a pH between about 7 and 8. 6. The process of claim 1 wherein said carp or pig organ is liver, spleen, intestines, thymus or testes. 7. The process of claim 1 wherein said acid is acetic acid. 8. The process of claim 1 wherein said precipitate is recovered by filtration or centrifugation. 9. A process for preparing pharmaceutical preparations of nucleoproteic material for administration to a subject for treatment of symptoms of neoplastic diseases which comprises: immersing carp thymus, spleen or intestines; pig intestines; or mixtures thereof into water having a pH between about 7 and 8 for a sufficient time to form a solution of nucleoproteins; adding a sufficient amount of an acid to form a precipitate of nucleoproteic material in suspension in said solution; filtering or centrifuging said suspension to recover said nucleoproteic material precipitate; washing the precipitate with distilled water; reseparating the precipitate by centrifugation or filtration; sterilizing said nucleoproteic precipitate; and preparing a formulation comprising a sterile water or saline suspension containing about 5 to 50% of said sterilized nucleoproteic precipitate. 10. A pharmaceutical composition of nucleoproteic material produced according to the process of claim 1. 11. A pharmaceutical composition of nucleoprotein material produced according to the process of claim 9. 12. A process for preparing pharmaceutical preparations of nucleoproteic materials for administration to a subject for treatment of symptoms of neuroplastic diseases which comprises: immersing carp thymus, pig intestines or mixtures thereof into an alkaline solution having a pH of between 7 and 8 for a sufficient time to extract nucleoproteins and form a solution thereof; adding a sufficient amount of acetic acid to form a precipitate of nucleoproteic material in suspension in said solution; filtering or centrifuging said suspension to recover said nucleoproteic material precipitate; washing the precipitate with distilled water; reseparating the precipitate by centrifugation of filtration; treating the precipitate with an alkaline agent to obtain a pH therefor of between about 5 and 6.5; sterilizing said nucleoproteic precipitate; and preparing a formulation comprising a sterile water or on saline suspension containing about 5 to 50% of said sterilized on nucleoproteic precipitate. 13. The process of claim 12 wherein the suspension comprises between 20 and 35% of the nucleoproteic precipitate. 14. The process of claim 9 wherein the suspension comprises between 20 and 35% of the nucleoproteic precipitate. 15. The process of claim 1 wherein the suspension comprises between 20 and 35% of the nucleoproteic precipitate. 16. The process of claim 12 wherein the water is heated to boiling to facilitate the extraction of said nucleoproteins. 17. The process of claim 9 wherein the water is heated to boiling to facilitate the extraction of said nucleoproteins. 18. A pharmaceutical composition of nucleoproteic material produced according to the process of claim 12.

Details for Patent 4,701,442

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-23